Search results for: rare disease

Indication based pricing

In the current climate of tighter budgetary controls and greater price scrutiny, a uniform pricing s...

Read more
Playing the Long Game: How Early Scientific Advice...

Early HTA scientific advice reduces price and reimbursement risk by informing ev...

Read more
Designing Payer-Ready Trials in 2025: Five Decisio...

Clinical innovation has never moved faster. Tools like single-arm designs, novel surrogates, and ada...

Read more
Building the bridge to access: Leveraging RWE from...

Objectives:  ​​Early-access schemes enable patients to access promising therapies—particularl...

Read more
Innovative Payment Models: Outcomes‑Based, Annui...

In 2010, the world’s most expensive therapy was Soliris (eculizumab), costing around USD 409,500 p...

Read more
US Biotech, what is the latest on Trump’s two ...

To date, there are two different levers in play under Trump’s “Most Favored Nation”, 1. A drug...

Read more
25 Years of NICE: Reflections and Achievements

Celebrating its 25th anniversary, NICE hosted a conference looking back at its progress and ahead to...

Read more
What are the current unmet needs in Oncology?

We explore the innovative assessment criteria for novel cancer therapies and the unmet needs in onco...

Read more
What is a fair value for oncology combination pric...

We explore the issues faced by manufacturers and payers for oncology combination pricing and the pot...

Read more
ISPOR US 2023: How do the reimbursement opportunit...

Our research compares and contrasts the reimbursement landscapes of digital health applications (DHA...

Read more
Older
Newer

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.

Talk to an expert

Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​

Get in touch